N/A
N=503
AsseSSing Impact in pSoriatic Treatment
Psoriatic Arthritis
Bottom Line
View on ClinicalTrials.gov: NCT05171270 ↗Enrolled (actual)
503
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Number of Patients Undergoing Treatment Escalation — 160 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Questionnaire (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Oxford
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Patients Undergoing Treatment Escalation |
160 | — |
| SECONDARY Number of Patients Undergoing Reduction of Therapy |
22 | — |
| SECONDARY Mean PsAID-12 Scores |
3.6 | — |
| SECONDARY Median CollaboRATE Score |
9 | — |
| SECONDARY Median Perceived Efficacy on Patient-physician Interaction Score (PEPPI) |
23 | — |
| SECONDARY Median Score for Physicians Opinion of How PsAID 12 Influenced Treatment Decision |
3 | — |
Summary
Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves trial and error to find the right medication for the right person. Very little is known about the decisions made to increase treatment in individual patients. Previous research in rheumatoid arthritis found that clinical measures of disease activity, patient reported outcomes and characteristics of the treating doctor all influenced the decision to change therapy in routine practice.
This investigators particularly want to establish whether routine use of the psoriatic arthritis impact of disease (PsAID-12) questionnaire in the clinic setting can enable a better understanding of the impact of PsA on each individual, improve physician-patient communication and lead to appropriate interventions. The PsAID-12 questionnaire is a relatively new European developed questionnaire measuring patient impact across 12 different domains in PsA.
This study will use routine implementation of the PsAID-12 questionnaire and see if this is related to treatment decisions and patient satisfaction. The investigators will also examine other factors that may influence treatment decisions including patient characteristics, physician characteristics, disease activity and quality of patient-physician interactions.
Eligibility Criteria
Inclusion Criteria
- Participant is willing and able to give informed consent for participation in the study and complete questionnaires in the local language.
- Aged 18 years or above.
- Diagnosed with PsA according to the ClASification of Psoriatic ARthritis (CASPAR) criteria and diagnosis confirmed by a rheumatologist (Taylor 2006).
Exclusion Criteria
- Patients who don't speak or read the local language
- Patients who are not comfortable filling in an app-based questionnaire or paper CRF.
- Patients with a new diagnosis of PsA at the current clinic visit
Data sourced from ClinicalTrials.gov (NCT05171270). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.